{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Daar ES"],"funding":["NCATS NIH HHS","NCRR NIH HHS","NIAID NIH HHS"],"pagination":["445-56"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3430716"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["154(7)"],"pubmed_abstract":["<h4>Background</h4>Limited data compare once-daily options for initial therapy for HIV-1.<h4>Objective</h4>To compare time to virologic failure; first grade-3 or -4 sign, symptom, or laboratory abnormality (safety); and change or discontinuation of regimen (tolerability) for atazanavir plus ritonavir with efavirenz-containing initial therapy for HIV-1.<h4>Design</h4>A randomized equivalence trial accrued from September 2005 to November 2007, with median follow-up of 138 weeks. Regimens were assigned by using a central computer, stratified by screening HIV-1 RNA level less than 100 000 copies/mL or 100 000 copies/mL or greater; blinding was known only to the site pharmacist. (ClinicalTrials.gov registration number: NCT00118898)<h4>Setting</h4>59 AIDS Clinical Trials Group sites in the Unite"],"journal":["Annals of internal medicine"],"pubmed_title":["Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1."],"pmcid":["PMC3430716"],"funding_grant_id":["UL1 RR024160","U01 AI068636-05","5U01 AI069484-02","AI069424","AI27661","RR024996","U01 AI069484","U01 AI038858","R01 AI058740-09","AI032782","AI27666","UL1 RR025747-04","U01 AI038855","U01 AI046376-05S4","U01 AI025868-18","1UL1 RR025777-01","N01 AI72626","U01 AI069452-03","RR00046","UL1 RR025008","UL1 RR024156","UO1 AI025859","AI069439","UM1 AI069511","UM1 AI069477","P30 AI073961","U01 AI046370-05","AI069434","UL1 TR000124","U01 AI069495","5U01 AI069428","U01 AI069494","U01 AI069472-05","U01 AI069472-01","U01 AI069472-03","5U01 AI069470-03","AI69501","AI69465","U01 AI069419","R01 AI058740","U01 AI069418","UL1 RR025777","U01 AI069532-05","P30 AI045008","U01 AI069423-05","U01 AI069532","U01 AI069415","AI34853","3U01 AI046376 05S4","P30 AI027757","AI58740","UL1 TR000454","RR025747","5U01 AI069418","5U01 AI069415-03","5P30 AI045008-10","U01 AI069419-05","AI25868","U01 AI069428-05","U01 AI027666-18","1U01 AI069494-01","U01 AI069501","U01 AI069467","P30 AI073961-05","U01 AI069447-03","U01 AI069439-05","U01 AI069471","U01 AI069470","AI069532","U01 AI069472","U01 AI046370","U01 AI069495-05","U01 AI032782","U01 AI069470-03","AI069495","U01 AI069470-05","UL1 RR024160-05","U01 AI032782-13","U01 AI069513-05","U01 AI025859-18","U01 AI025859","U01 AI069474","U01 AI046376","U01 AI069477","U01 AI069467-01","U01 AI069484-02","U01 AI069467-03","U01 AI069511","U01 AI069513","AI069501","UM1 AI068634","1UL1 RR024156","U01 AI038858-05","U01 AI069471-05","5U01 AI069470","U01 AI034853","U01 AI069494-01","5U01 AI069471","AI073961","AI69419","U01 AI068636","UL1 RR024996","U01 AI025868","U01 AI068634","AI46370","U01 AI069447","1UO1 AI069494-01","AI069513","U54 RR023561","U01 AI027658","AI069477","AI069474","AI069472","AI069471","1U01 AI069502-01","AI69423","U01 AI027661-19","U01 AI027661-18","U01 AI027658-18","U01 AI069511-06","UL1 RR025777-01","1U01 AI069472-01","AI50410","1U01 AI69467-01","U01 AI069452","U01AI068636","P30 AI050410","AI38858","U01 AI068634-05","U01 AI069501-05","U01 AI027666","U01 AI069415-03","AI38855","P30 AI045008-10","U01 AI069428","AI69556","AI69432","UL1 RR025747","U01 AI069424-05","U01 AI034853-12","U01 AI069556-05","UL1 RR024156-05","U01 AI069424","U01 AI069423","U01 AI027661","P30 AI050410-14","5U01 AI069447","U01 AI069418-05","AI27675","M01 RR000046-41","U01 AI069474-05","P30 AI050409","U01 AI069477-05","U01 AI069439","U01 AI069432-05","AI68634","M01 RR000046","U01 AI069432","U01 AI069556","RR025780","UL1 RR024996-05"],"pubmed_authors":["Patterson H","Ray G","Patterson K","Smith KY","Meier JL","Pollard RB","Hughes V","Gripshover B","Lane TW","Balfour HH","Pfister S","Jahed NC","Yin MT","Hughes S","Ragan D","Goldman M","Thal G","Saemann M","James T","Marrero S","Pahwa S","Jarocki B","Dunaway SB","Mollan K","Benson CA","Jain M","Epperson K","Boyce C","Loquere A","Moe A","Swindells S","OBrien WA","Sax PE","Descallar R","Chelsea C","Demeter L","Miller M","Thomas A","Corales R","Zadzilka A","Lopez R","Hurley C","Albrecht M","El Sadr W","Collier AC","Camp R","Santana JL","Van Meter F","El-Daher N","Burgett-Yandow N","Revuelta M","Shore J","Norris J","Olusanya A","Katzenstein D","Lindsey E","Davis CE","Casey G","McMahon D","Timpone J","Kalayjian R","Bolivar H","Adams B","Taiwo B","Ukwu M","Cheng A","Rutecki B","Mong-Kryspin L","Silberman M","Boston M","Koletar SL","Megill C","Swiatek JA","Rooney JF","Pittard D","Adams M","Currin D","Stapleton JT","Zimmerman E","Wiggins I","Colon L","Feinberg J","Skolnik PR","Henry K","Luetkemeyer A","Hsaio CB","Wulfsohn M","Ashton C","Budhathoki C","Farajallah A","Hammer SM","Kumar P","Maffei K","Antosh D","Fox KA","Woodward WC","Mildvan D","Bloom A","Bischofberger N","Daar ES","Myers L","Martinez A","Pollard R","Cox GM","Robbins G","Gochnour D","Tashima KT","Rodriguez M","Deaconess BI","Fischl MA","Shaik S","del Rio C","Geiseler J","Funk CA","Youmans A","Johnson S","Lennox J","Johnson T","Morse G","AIDS Clinical Trials Group Study A5202 Team","Rogers L","Pappa KA","Jackson B","Ha B","Delaney J","Whitely K","Shulman N","Reisler R","Vasquez M","Morse GD","Gross R","Daskalakis D","Tierney C","Navarro S","Smith K","Godfrey C","Seefried E","Valle S","Storey SS","Gothing J","Reid J","Kim GY","Payne M","Palmer M","Petersen T","Hoffman JH","Morgan M","Bordenave B"],"additional_accession":[]},"is_claimable":false,"name":"Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.","description":"<h4>Background</h4>Limited data compare once-daily options for initial therapy for HIV-1.<h4>Objective</h4>To compare time to virologic failure; first grade-3 or -4 sign, symptom, or laboratory abnormality (safety); and change or discontinuation of regimen (tolerability) for atazanavir plus ritonavir with efavirenz-containing initial therapy for HIV-1.<h4>Design</h4>A randomized equivalence trial accrued from September 2005 to November 2007, with median follow-up of 138 weeks. Regimens were assigned by using a central computer, stratified by screening HIV-1 RNA level less than 100 000 copies/mL or 100 000 copies/mL or greater; blinding was known only to the site pharmacist. (ClinicalTrials.gov registration number: NCT00118898)<h4>Setting</h4>59 AIDS Clinical Trials Group sites in the Unite","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Apr","modification":"2025-04-04T14:42:43.087Z","creation":"2019-03-27T00:57:18Z"},"accession":"S-EPMC3430716","cross_references":{"pubmed":["21320923"],"doi":["10.1059/0003-4819-154-7-201104050-00316","10.7326/0003-4819-154-7-201104050-00316"]}}